EA004428B1 - Модифицированные экзосомы и их применение - Google Patents

Модифицированные экзосомы и их применение Download PDF

Info

Publication number
EA004428B1
EA004428B1 EA200100509A EA200100509A EA004428B1 EA 004428 B1 EA004428 B1 EA 004428B1 EA 200100509 A EA200100509 A EA 200100509A EA 200100509 A EA200100509 A EA 200100509A EA 004428 B1 EA004428 B1 EA 004428B1
Authority
EA
Eurasian Patent Office
Prior art keywords
molecule
cell
recombinant
peptide
exosomes
Prior art date
Application number
EA200100509A
Other languages
English (en)
Russian (ru)
Other versions
EA200100509A1 (ru
Inventor
Филипп Бенарош
Элен Венсан-Шнейдер
Памела Штумптнер
Себастьян Амигорена
Кристиан Боннеро
Граса Рапосо
Original Assignee
Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Энститю Кюри
Сантр Насьональ Де Ля Решерш Сьентифик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль, Энститю Кюри, Сантр Насьональ Де Ля Решерш Сьентифик filed Critical Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Publication of EA200100509A1 publication Critical patent/EA200100509A1/ru
Publication of EA004428B1 publication Critical patent/EA004428B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
EA200100509A 1998-11-05 1999-11-04 Модифицированные экзосомы и их применение EA004428B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9813946A FR2785543B1 (fr) 1998-11-05 1998-11-05 Exosomes modifies et utilisations
PCT/FR1999/002691 WO2000028001A1 (fr) 1998-11-05 1999-11-04 Exosomes modifies et utilisations

Publications (2)

Publication Number Publication Date
EA200100509A1 EA200100509A1 (ru) 2001-12-24
EA004428B1 true EA004428B1 (ru) 2004-04-29

Family

ID=9532412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100509A EA004428B1 (ru) 1998-11-05 1999-11-04 Модифицированные экзосомы и их применение

Country Status (10)

Country Link
EP (1) EP1127110A1 (fr)
JP (1) JP2002529074A (fr)
CN (1) CN1325441A (fr)
AU (2) AU772451B2 (fr)
CA (1) CA2349679A1 (fr)
EA (1) EA004428B1 (fr)
FR (1) FR2785543B1 (fr)
IL (1) IL142634A0 (fr)
TW (1) TWI224138B (fr)
WO (1) WO2000028001A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
IL160142A0 (en) 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
CN1313151C (zh) * 2002-11-04 2007-05-02 杭州浙大康泰生物技术有限公司 一种新型高效非细胞性疫苗的制备及其用途
JP4939926B2 (ja) 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
JPWO2005094571A1 (ja) * 2004-03-31 2008-02-14 独立行政法人科学技術振興機構 遺伝子改変ヘテロ動物及び該動物を用いたエキソサイトシスの計測方法
WO2006089572A1 (fr) * 2005-02-28 2006-08-31 Charité - Universitätsmedizin Berlin Capsules polyelectrolytiques de detection des reactions entre antigenes et anticorps
CN1322115C (zh) * 2005-07-06 2007-06-20 清华大学 载有外源配体分子的胞外体及其制备方法与应用
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN101641010A (zh) 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 用作疫苗的外来体组分的修饰
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
CN102596177B (zh) * 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
KR20120081972A (ko) * 2009-07-02 2012-07-20 아이티에이치 임뮨 세라피 홀딩스 에이비 엑소좀에 기초한 암의 치료
ES2362589B1 (es) 2009-12-28 2012-05-16 Centre De Recerca En Salut Internacional De Barcelona Exosomas derivados de reticulocitos infectados con plasmodium sp., método para su obtención y su uso.
EP2785839A2 (fr) 2011-11-30 2014-10-08 University of Bremen Expression d'arnmi dans le tissu placentaire
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP3052616A4 (fr) * 2013-10-02 2017-03-29 Paradigm Biopharmaceuticals Limited Procédé de production d'exosomes
EP2862874B1 (fr) * 2013-10-15 2018-12-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procédé de production d'anticorps polyclonaux à l'aide d'une composition antigénique comprenant des vésicules de membrane contenant des protéines
DE102014113688A1 (de) * 2014-09-22 2016-03-24 Jacobs University Bremen Ggmbh Antigenspezifische immunfärbung von t-zellen
WO2016149358A1 (fr) * 2015-03-16 2016-09-22 Duncan Ross Procédé de traitement comprenant des vésicules logées dans une membrane
RU2763524C2 (ru) * 2015-06-03 2021-12-30 Инновекс Терапеутикс, С.Л. Экзосомы и их применение в качестве вакцины
EP3307890A1 (fr) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Utilisation d'exosomes pour le traitement de maladies
AU2017226956A1 (en) 2016-03-03 2018-10-11 Institut Gustave Roussy PTPS-based vaccines against cancer
US20190112351A1 (en) 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
EP3801028A4 (fr) 2018-05-30 2022-04-13 Direct Biologics LLC Additif congelé ou en poudre de facteur de croissance et de vésicule extracellulaire comprenant une préparation de cellules souches mésenchymateuses (msc) et méthodes d'utilisation
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN110938670B (zh) * 2019-11-07 2023-11-07 南方医科大学南方医院 微生物菌液与血清囊泡反应在检测微生物感染中的应用
WO2021172595A1 (fr) * 2020-02-28 2021-09-02 国立大学法人金沢大学 Vésicule extracellulaire de présentation d'antigène, composition contenant celle-ci, et procédé destiné à la fabrication de celles-ci
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
JP2021000093A (ja) * 2020-08-05 2021-01-07 国立研究開発法人医薬基盤・健康・栄養研究所 エキソソーム標的ｄｎａワクチン
EP4537820A1 (fr) 2023-10-13 2025-04-16 Institut Gustave-Roussy Composé et combinaisons comprenant ledit composé pour améliorer une réponse immunitaire
EP4574155A1 (fr) 2023-12-22 2025-06-25 Christine Süßmuth Molécules destinées à être utilisées dans la régénération et le rajeunissement cellulaires
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005900A1 (fr) * 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Vesicules presentant des antigenes obtenues a partir de cellules

Also Published As

Publication number Publication date
EP1127110A1 (fr) 2001-08-29
WO2000028001A1 (fr) 2000-05-18
AU1051400A (en) 2000-05-29
AU2004203482A1 (en) 2004-08-26
CA2349679A1 (fr) 2000-05-18
CN1325441A (zh) 2001-12-05
TWI224138B (en) 2004-11-21
JP2002529074A (ja) 2002-09-10
FR2785543B1 (fr) 2003-02-28
FR2785543A1 (fr) 2000-05-12
AU772451B2 (en) 2004-04-29
EA200100509A1 (ru) 2001-12-24
IL142634A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
EA004428B1 (ru) Модифицированные экзосомы и их применение
AU2017312361B2 (en) T cell receptors and immune therapy using the same
Lake et al. Production and characterization of cytotoxic Thy‐1 antibody‐secreting hybrid cell lines Detection of T cell subsets
JP4939926B2 (ja) 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
US11939376B2 (en) T cell receptors and immune therapy using the same
US5840504A (en) Method for separating sex specific molecules and non-sex specific molecules
JP2001513624A (ja) 独特な樹状細胞関連型ｃ型レクチンであるデクチン−１、およびデクチン−２；組成物ならびにその使用
JP2019507582A (ja) 免疫療法用のｓｌｃ４５ａ２ペプチド
AU2022268348B2 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
US20240293459A1 (en) Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of use
AU2009246044B2 (en) Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells
WO1995016775A1 (fr) Fusions de cellules tumorales et procedes d'utilisation de telles fusions de cellules tumorales
KR20010075418A (ko) 유방 특이적으로 분비되는 유방암 단백질인 마마글로빈
KR102381854B1 (ko) T 세포 수용체 및 이를 사용하는 면역 요법
JP2006524489A (ja) Ｓｐｅｘ組成物および使用方法
US20030165479A1 (en) Methods for isolating proteins expressed by dendritic cells
JPH03112486A (ja) Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
WO1996012009A2 (fr) Procedes de genie genetique permettant la realisation de cellules presentant des antigenes
JPH03112485A (ja) Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
McCluskey et al. Cell surface expression of the amino-terminal domain of A kappa alpha. Recognition of an isolated MHC antigenic structure by allospecific T cells but not alloantibodies.
HK40071461A (en) T cell receptors and immune therapy using the same
Shimamura et al. Haematopoietic cell lines capable of colonizing the thymus following in vivo transfer expressed T-cell receptor gamma-gene immature mRNA
ANTIBODY VITRO DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CONNECTIVE TISSUE PROTEINS
Engel Monoclonal antibodies to rat major histocompatability antigens
HK40010473B (en) T cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU